4-(4-Fluoroindazol-1-yl)aniline | 1330064-84-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(4-Fluoroindazol-1-yl)aniline
• 英文别名: 4-(4-fluoroindazol-1-yl)aniline
• CAS: 1330064-84-0
• 化学式: C₁₃H₁₀FN₃
• 分子量: 227.241
• InChiKey: KOZZHHNTDCGGLQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(4-Fluoroindazol-1-yl)aniline 、 4-氯-3-三氟甲基异氰酸苯酯 以 甲醇 、 二氯甲烷 为溶剂， 以36%的产率得到1-[4-Chloro-3-(trifluoromethyl)phenyl]-3-[4-(4-fluoroindazol-1-yl)phenyl]urea
  参考文献：
  名称：

  Synthesis of indazole based diarylurea derivatives and their antiproliferative activity against tumor cell lines

  摘要：

  New series of indazole based diarylureas were synthesized and their anticancer activity against cancer cells H460, A549, OS-RC-2, HT-29, Lovo, HepG2, Bel-7402, SGC-7901 and MDA-MB-231 were examined. These derivatives of diarylureas, except azaindazole based diarylureas 5f, 51 and 5m, showed superior or similar activity against most of these selected cancer cell lines to the reference compound sorafenib. The effect of substituents on the indazole ring was also investigated. Derivatives with trifluoromenthy or halogen substituents on the indazole ring showed higher activity against the selected cancer cell lines than sorafenib. The acute toxicity assay showed that compounds 5a, 5b and 5i possessed lower toxicity than sorafenib. Compound 5i with 4-(trifluoromenthy)-1H-indazole and 4-(trifluoromenthy) benzene moieties exhibited the most potent anticancer activity. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.02.034
• 作为产物：
  描述：

  4-氟-1H-吲唑 在 盐酸 、 碳酸氢钠 、 magnesium sulfate 、 caesium carbonate 、 tin(ll) chloride 作用下， 以 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-(4-Fluoroindazol-1-yl)aniline
  参考文献：
  名称：

  Synthesis of indazole based diarylurea derivatives and their antiproliferative activity against tumor cell lines

  摘要：

  New series of indazole based diarylureas were synthesized and their anticancer activity against cancer cells H460, A549, OS-RC-2, HT-29, Lovo, HepG2, Bel-7402, SGC-7901 and MDA-MB-231 were examined. These derivatives of diarylureas, except azaindazole based diarylureas 5f, 51 and 5m, showed superior or similar activity against most of these selected cancer cell lines to the reference compound sorafenib. The effect of substituents on the indazole ring was also investigated. Derivatives with trifluoromenthy or halogen substituents on the indazole ring showed higher activity against the selected cancer cell lines than sorafenib. The acute toxicity assay showed that compounds 5a, 5b and 5i possessed lower toxicity than sorafenib. Compound 5i with 4-(trifluoromenthy)-1H-indazole and 4-(trifluoromenthy) benzene moieties exhibited the most potent anticancer activity. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.02.034